Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is among the 15 Best Small Cap Stocks to Buy According to Wall Street. Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating On February 4, 2026, Barclays raised its price target on CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $10 from $8 and maintained an Overweight rating as part of a fourth-quarter earnings preview for the biotechnology group. Earlier, on January 20, 2026, Piper Sandler lifted its price tar ...